Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p85
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 85/312)
Character Range: 15994332–16003048

minimal trauma; AND
                                                                                                                           Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition.
                                                                                                                           The fracture must have been demonstrated radiologically and the year of plain x-ray or computed tomography (CT) scan or magnetic resonance imaging (MRI) scan must be documented in the patient's medical records when treatment is initiated.
                                                                                                                           A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
C14994              P14994         CN14994          Minoxidil                                                              Severe refractory hypertension
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The treatment must be initiated by a consultant physician.
C15004              P15004         CN15004          Dutasteride with tamsulosin                                            Benign prostatic hyperplasia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures - Streamlined Authority Code 15004
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must have lower urinary tract symptoms; AND
                                                                                                                           Patient must have moderate to severe benign prostatic hyperplasia.
C15005              P15005         CN15005          Cabergoline                                                            Pathological hyperprolactinaemia
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                    Quinagolide                                                            Patient must have had surgery for this condition with incomplete resolution.

C15006              P15006         CN15006          Oxybutynin                                                             Detrusor overactivity
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must be unable to tolerate oral oxybutynin.  or
                                                                                                                           Patient must be unable to swallow oral oxybutynin.
C15007              P15007         CN15007          Medroxyprogesterone                                                    Advanced breast cancer
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The condition must be hormone receptor positive.
C15009              P15009         CN15009          Eprosartan                                                             Transfer to a base-priced drug would cause patient confusion resulting in problems with compliance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C15011              P15011         CN15011          Alendronic acid with colecalciferol                                    Osteoporosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Compliance with Authority Required procedures - Streamlined Authority Code 15011
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient;
                                                                                                                           Patient must be aged 70 years or older;
                                                                                                                           Patient must have a Bone Mineral Density (BMD) T-score of -2.5 or less; AND
                                                                                                                           Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition.
                                                                                                                           The date, site (femoral neck